Replies to post #521026 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Investors didn’t buy NVCR and Optune’s future outlook as new technologies emerge. NVCR is down to a third of its high of about $200 just over a year ago in June. Investors are headed for exits it seems … insider sales too.

But we appreciate your opinions about NWBO.